Related by context. All words. (Click for frequent words.) 71 Chemical Entity NCE 62 Drug Applications NDAs 61 Drug Submission 60 Lixisenatide 60 Ciclesonide 60 Engl J Med 59 Drug Submission NDS 59 BAL# [002] 58 Glatiramer Acetate 57 Alvesco R 57 Dalbavancin 57 Clofarabine 57 Mycophenolate Mofetil 57 Receptor Agonist 57 RhuDex 56 Mipomersen 56 Noxafil 56 Therapeutic Vaccine 56 Aliskiren 56 Aeterna Zentaris Inc 56 Trandolapril 56 Iloperidone 56 Tamsulosin 56 Pazopanib 55 Anidulafungin 55 Dasatinib 55 Roflumilast 55 AZILECT R 55 Oglemilast 55 Darunavir 55 Rheumatoid Arthritis Drug 55 GW# [003] 55 Drug Shows Promise 55 Pharmacokinetic Study 55 Muraglitazar 55 balsalazide tablet 55 Aptamer 55 Etravirine 55 Pafuramidine 55 Velcade bortezomib 55 Collaborators Publish 55 Temsirolimus 55 Lupus Drug 55 Molecular Entities 55 Liprotamase 55 Small Molecule Drug 54 Drug Candidate 54 Fondaparinux 54 Ixabepilone 54 BioGard 54 Nicotine Vaccine 54 Arimoclomol 54 Anticancer Agent 54 JAK Inhibitor 54 Safinamide 54 Aviptadil 54 Phase III Clinical Trial 54 GSK# [001] 54 Nitazoxanide 54 Migraine Drug 54 Investigational Compound 54 Onconase 54 receptor tyrosine kinase inhibitor 54 Stakeholder Opinions 54 STEDESA 54 Interferon Alpha 54 Febuxostat 54 Phase III Clinical Trials 54 Avanafil 54 Milnacipran 54 Japanese Encephalitis vaccine 53 proteasome inhibitor 53 YONDELIS 53 Multiple Ascending Dose 53 Oral Insulin 53 Levofloxacin 53 Loxapine 53 Fingolimod 53 KRN# 53 oral antiviral 53 Orapred ODT 53 Valtropin 53 Initiates Clinical 53 Investigational 53 phase Ib 53 Cancidas 53 Preclinical Data 53 Tablet Formulation 53 Indomethacin 53 Amlodipine Besylate 53 Vernakalant 53 Cladribine 53 Silodosin 53 Zenapax 53 Clinical Study Shows 53 Moxifloxacin 53 Prodrug 53 Ranolazine 53 Archexin 53 Schizophrenia Drug 53 EVIZON TM 53 cathepsin K inhibitor 53 Guidelines Recommend 53 Transdermal Patch 53 Elesclomol 53 Maribavir 53 RAPAFLO 53 AZILECT ® 53 PDE4 inhibitor 53 Eli Lilly Cymbalta 53 Alvesco ® 53 Levetiracetam 53 acting muscarinic antagonist 53 Vidaza azacitidine 53 Oxytrex TM 53 Zebinix R 53 Successfully Completes Phase 53 Teysuno 53 Orphan Designation 53 Integrase Inhibitor 53 Omalizumab 53 Eltrombopag 53 Lung Cancer Drug 53 Melphalan 53 Investigational Treatment 53 Serdolect ® 53 Plicera 53 Sutent sunitinib 53 Tuberculosis Vaccine 53 Cancer Vaccines 52 Bayer Onyx 52 Systemic Delivery 52 Study Showed 52 Small Molecule 52 Ganciclovir 52 Dacogen decitabine 52 Prostate Cancer Vaccine 52 Glybera R 52 Bazedoxifene 52 vemurafenib 52 Dapagliflozin 52 fluoroquinolone antibiotic 52 Oral Spray 52 Curaxin 52 Anavex #-# 52 UPLYSO 52 PDUFA Date 52 quinolone antibiotic 52 Humira adalimumab 52 IND Application 52 Lopinavir 52 Vertex hepatitis C 52 Ozarelix 52 PrevOnco 52 Plenaxis TM 52 Romidepsin 52 JAK inhibitor 52 novel oral anticoagulant 52 miconazole Lauriad ® 52 Pertuzumab 52 Files IND 52 Montelukast 52 PHX# 52 Ceftobiprole 52 Delhi Metallo 52 GRAS Status 52 Vidofludimus 52 ONGLYZA ™ 52 Diabetic Nephropathy 52 Albugon 52 Pivotal Phase III 52 Entecavir 52 PNT# 52 TB Vaccine 52 Argatroban 52 Naproxcinod 52 Eribulin 52 Vilazodone 52 Lenalidomide 52 CONBRIZA 52 Receives Orphan Drug 52 Mycamine 52 GeneICE 52 ADVANCE PD 52 Fabry Disease 52 Drug Applications INDs 52 polymerase inhibitor 52 Cellcept 52 Cefuroxime Axetil 52 Panzem R NCD 52 OvaDx 52 Investigational Drug 52 Alferon N 52 Stedesa 52 CG# [003] 52 Lubiprostone 52 Arzerra ofatumumab 52 Trobalt 52 Alexion Soliris 52 Firazyr 52 Saquinavir 52 Enzyme Replacement Therapy 52 outlicensed 52 Product Commercialization 52 seliciclib CYC# 52 mTOR inhibitor 52 Aflibercept 52 casopitant 52 Telbivudine 52 Laquinimod 51 LAF# 51 Stalevo ® 51 Zenvia Phase III 51 Pirfenidone 51 Interferon alpha 51 inhalation powder 51 Onrigin 51 RNAi Therapeutics 51 Phase 2a Clinical Trial 51 Recombinant Human 51 Submits NDA 51 Respiratory Virus 51 Azathioprine 51 Bremelanotide 51 RhuDex ® 51 Tumor Targeting 51 OvaRex ® MAb 51 Nasdaq ACHN 51 DORIBAX 51 Medoxomil 51 Deferiprone 51 Aurora Kinase 51 topical ophthalmic 51 CCR5 antagonist 51 Belerofon 51 phase IIa clinical 51 Phase III PREGNANT PROCHIEVE 51 Pivotal Study 51 Saforis 51 FDA Approvals 51 TREDAPTIVE 51 mesylate 51 Crofelemer 51 Psoriasis Drug 51 Sanvar 51 TBC# 51 ELND# 51 Fluconazole 51 acyclovir Lauriad R 51 Fast Track Status 51 Sebivo 51 Phase 2a Trial 51 Phase Ib study 51 vismodegib 51 entity NCE 51 Diagnostics FIND 51 Alemtuzumab 51 Rotavirus Vaccine 51 CEQ# 51 Panzem ® 51 Amrubicin 51 Altastaph 51 orally dosed 51 Granted Orphan Drug 51 PREGNANT PROCHIEVE ® 51 alefacept 51 Onco TCS 51 Novel Antibiotic 51 CAMMS# 51 anticancer agent 51 Therapeutic Competitors Companies 51 Protease Inhibitor 51 REMINYL ® 51 Carbidopa Levodopa 51 USL# 51 Advagraf 51 Seasonal Influenza Vaccine 51 therapeutic monoclonal antibody 51 targeted radiotherapeutic 51 Topiramate 51 Gleevec Glivec 51 Simulect 51 Initiate Phase 51 Ofatumumab 51 Cholesterol Lowering Drug 51 BLP# Liposome Vaccine 51 desvenlafaxine 51 orally disintegrating 51 Cethromycin 51 HIV integrase inhibitor 51 Pimavanserin 51 glucokinase activator 51 Taligen Therapeutics 51 Gout Drug 51 IL# PE#QQR 51 Levoleucovorin 51 ketolide antibiotic 51 Velaglucerase Alfa 51 fluvoxamine maleate 51 Orphan Status 51 Actimmune ® 51 glatiramer 51 Sunovion 51 LEUKINE 51 mertansine 51 Tesamorelin 51 dalbavancin 51 Saxagliptin 51 phase IIa 51 aripiprazole Abilify 51 anti CD3 monoclonal 50 Extended Release 50 Kinase Inhibitor 50 SinuNase ™ 50 Phase III Trial 50 Octreotide 50 generation purine nucleoside 50 Meets Primary Endpoint 50 phase III isavuconazole 50 elotuzumab 50 Initiates Phase II 50 donepezil hydrochloride 50 MAGE A3 ASCI 50 Topical Cream 50 Initiate Clinical Trial 50 Scottish Motion Tabled 50 Clinical Trial Results 50 ARIXTRA R 50 Extina 50 Prognostic Value 50 LibiGel ® 50 Sanofi Aventis Taxotere 50 Daclizumab 50 Phase Ib II 50 Ustekinumab 50 Orazol 50 Clevudine 50 Biomarker Study 50 Iluvien ® 50 NVA# 50 Torisel 50 Vicriviroc 50 beta 1a 50 AOD# [002] 50 ganaxolone 50 GATTEX TM 50 histamine dihydrochloride 50 reslizumab 50 FOLOTYN ® 50 Inhalation Solution 50 NDA resubmission 50 Granulocyte Colony Stimulating Factor 50 FDA Approvable Letter 50 HQK 50 XYOTAX TM 50 Antiangiogenic 50 Eculizumab 50 Phase 2b Trial 50 RESOLOR 50 torezolid 50 Ridaforolimus 50 HDAC Inhibitor 50 Universal Flu Vaccine 50 Fodosine 50 Tyzeka Sebivo 50 Guanilib 50 Insulin Delivery Systems 50 preclinical toxicology 50 injectable formulations 50 TYZEKA 50 phase IIb 50 Prolongs Survival 50 Extending GestatioN 50 Kevetrin ™ 50 ACOMPLIA R 50 BRILINTA 50 etanercept Enbrel 50 Anticancer Agents 50 albiglutide 50 torezolid phosphate 50 Molecular Basis 50 triphendiol 50 Urocidin TM 50 Blinatumomab 50 PREOS R 50 PRN FDA Approves 50 Ticagrelor 50 HCV Protease Inhibitor 50 lixivaptan 50 Dyloject TM 50 Liposomal 50 Maleate 50 neuraminidase inhibitor 50 Begin Clinical Trials 50 Fixed Dose Combination 50 Omacetaxine 50 interferon beta 1b 50 Novel Therapeutic 50 lomitapide 50 Zegerid OTC 50 Tigecycline 50 Phase IIb Trial 50 Pancreate 50 Tasimelteon 50 Chemokine Receptor 50 Factor VIIa 50 Angiotensin Converting Enzyme 50 novel prodrug 50 Bicifadine 50 oral taxane 50 Sapacitabine 50 Carfilzomib 50 bosutinib 50 Influenza Vaccine 50 phase IIb clinical 50 Telavancin 50 Kamada AAT 50 Elvitegravir 50 Cethrin R 50 Keppra XR 50 Trovax 50 Vinorelbine 50 Aerosurf 50 RELOVAIR ™ 50 midstage trials 50 Alzhemed TM 50 Angiocept 50 Pivotal Trial 50 Oasmia 50 Terbinafine 50 vascular disrupting agent 49 phase IIb trial 49 RNAi Therapeutic 49 CDP# 49 tubulin inhibitor 49 methylnaltrexone 49 Phase IIb Clinical Trial 49 Generic Version Of 49 Tesmilifene 49 Presents Positive 49 Civacir 49 liprotamase 49 Spiegelmer ® 49 molecular entities NMEs 49 rasagiline tablets 49 MKC# MKC# PP 49 Inhalation Aerosol 49 ATL# [002] 49 Tolvaptan 49 small molecule thrombopoietin 49 Cellegesic 49 HuMax CD4 49 Zensana 49 Initiates Enrollment 49 Phase 1a clinical 49 Vaccine Candidate 49 HuMax TAC 49 Initiates Phase III 49 HCl Injection 49 Phase IIB 49 Dabigatran etexilate 49 OncoGel 49 rxRNA 49 GLP toxicology studies 49 Phase III psoriasis 49 AstraZeneca Symbicort 49 Receives Approvable Letter 49 randomized controlled Phase 49 Tumor Microenvironment 49 ZEFTERA TM Zevtera TM 49 Xanafide 49 Nanobody 49 ITAX 49 Approvable 49 Anti CD# Antibody 49 Vernalis plc 49 multicenter Phase III 49 methylnaltrexone bromide 49 cetuximab Erbitux R 49 JAK3 inhibitor 49 Davanat 49 GSK '# 49 RhuDex R 49 SYCREST 49 FDA Accepts 49 Phase III Trials 49 SERMs 49 Azacitidine 49 Anti Tumor 49 LIVALO 49 KNS # 49 UCB Keppra 49 topically administered 49 ATPace TM 49 Synera 49 BioSante Pharmaceuticals Announces 49 Patent Covering 49 udenafil 49 Pandemic Influenza Vaccine 49 prophylactic vaccine 49 Entocort 49 Monoclonal Antibody 49 Phase 2a Study 49 Glucophage XR 49 EpiCeram 49 StemEx 49 Decitabine 49 Cx# [002] 49 ToxCast TM 49 Phase #/#a 49 FACTIVE tablets 49 Ampligen ® 49 investigational humanized monoclonal antibody 49 Pivotal Trials 49 lucinactant 49 EOquin 49 alogliptin 49 rilonacept 49 maturation inhibitor 49 integrase inhibitor 49 Urocidin 49 Receives Orphan Drug Designation 49 Myocet 49 Cardio Vascu Grow 49 Expedited Review 49 SAFLUTAN 49 HCl capsules 49 PSN# [002] 49 Therapeutic Targets 49 MEVACOR 49 Omapro 49 Corlux 49 Phase Ib 49 therefore therapeutically equivalent 49 Sanctura XR 49 Qutenza TM 49 Tezampanel 49 OMP designation 49 VitiGam TM 49 Anthim 49 Extended Release Tablets 49 Ampligen r 49 Phase Ib clinical 49 Luveniq 49 QLT# 49 Personalised Medicine 49 Panzem R 49 Pegloticase 49 Submits Investigational 49 Demonstrates Potential 49 Santaris 49 Vitaros 49 TYGACIL 49 nucleoside analog 49 Raptiva R 49 Equetro 49 IgG1 monoclonal antibody 49 Keryx Biopharma 49 miconazole Lauriad R 49 Vascugel 49 Collategene 49 pharmacokinetic PK 49 Kinase Inhibitors 49 Orphan Drug Status 49 Glufosfamide 48 Varespladib 48 Rezonic 48 Generic Version 48 Arzerra TM 48 Teijin Pharma 48 Files Investigational 48 EP #R 48 Alvesco 48 Traficet EN 48 Adjuvant Treatment 48 PSN# [001] 48 Cetrorelix 48 Kepivance 48 SUTENT ® 48 Icatibant 48 Pluripotent Stem Cells 48 Voraxaze 48 investigational antibiotic 48 E1 INT TM 48 Hedgehog Pathway Inhibitor 48 Cellegesic TM nitroglycerin ointment 48 TPI ASM8 48 PreHistin TM 48 Phase IIb clinical trials 48 tramiprosate ALZHEMED TM 48 PD LID 48 vidofludimus 48 Dacogen injection 48 Betaferon R 48 Trodusquemine MSI 48 rPA anthrax vaccine 48 PF # [002] 48 Surfaxin LS 48 Arcalyst 48 Cerepro ® 48 5 HT3 antagonist 48 terlipressin 48 Presents Positive Preclinical 48 Marketing Authorisation Application MAA 48 Tesetaxel 48 Adentri 48 Biopartners 48 Hsp# Inhibitor 48 HIV Integrase 48 oral prodrug 48 Annamycin 48 PrevOnco ™ 48 Panzem 48 Cipralex ® 48 Loramyc R 48 Lovaza TM 48 oral salmon calcitonin 48 ATL# [001] 48 EndoTAG TM -1 48 Entry Inhibitor 48 IAP inhibitors 48 StemEx R 48 SILENOR 48 Phase #b/#a 48 Hexvix ® 48 HepeX B TM 48 Vimpat R 48 OvaRex R 48 PANVAC VF 48 Adult Stem Cell Therapy 48 Immunotherapeutic 48 Ramelteon 48 topical ocular 48 Phase IIa Clinical Trial 48 ISENTRESS raltegravir 48 Aurora kinase inhibitor 48 nanoviricides 48 Drug Application 48 Vfend 48 Cardiovascular Horizons 48 Proquin XR 48 gets USFDA nod 48 Phase 1b clinical 48 Aganocide 48 LUCASSIN 48 Hedgehog antagonist 48 Teva Provides Update 48 epoetin zeta 48 drug ISA# 48 Dermylex TM 48 Sustiva efavirenz 48 Tyvaso 48 SPRIX ® 48 CVac 48 Alogliptin 48 HepaSphere 48 toenail onychomycosis 48 Dose Ranging Study 48 Resubmission 48 OMAPRO ™ 48 Pennsaid R 48 Allegra Oral Suspension 48 VivaGel ™ 48 Injectafer 48 Completes Patient Enrollment 48 Pulmonary Arterial Hypertension 48 IND submission 48 Ceragenix 48 Present Preclinical Data 48 Pruvel 48 Pivotal Phase II 48 Glufast 48 Celgene Thalomid 48 Caprospinol 48 Initiates Clinical Trial 48 Lilly Cymbalta 48 BioMarck 48 DP VPA 48 LUNESTA TM 48 Iluvien TM 48 ERYtech Pharma 48 Fenoglide 48 Ramoplanin 48 Wound Dressing 48 Extended Release Capsules 48 Romiplostim 48 Inhaled Liposomal Ciprofloxacin 48 Welichem 48 Antimicrobial Coating 48 Imaging Techniques 48 Somatuline R Autogel R 48 Impavido R 48 Focalin XR R 48 Plexxikon proprietary 48 oral methylnaltrexone 48 Vidaza R 48 ONCONASE R 48 Mpex 48 Gamunex C 48 Indaflex 48 rabeprazole 48 Xyzal R 48 Ampligen 48 Tarceva TM 48 Allovectin 7 48 Campath ® 48 Anti Inflammatory Drug 48 Bayer Nexavar 47 faropenem 47 Actemra tocilizumab 47 BCR ABL inhibitors 47 Galenea 47 Tekturna HCT 47 sublingual tablets 47 SPRYCEL ® 47 Factive 47 CRMD# 47 Tyrosine Kinase Inhibitor 47 Tofacitinib 47 QRxPharma 47 Long Term Efficacy 47 Initiated Phase 47 Patient Enrolment 47 Boceprevir 47 Taclonex Scalp R 47 CCR5 receptor antagonist 47 zileuton 47 topical NSAID 47 sirtuin modulators 47 Japanese Encephalitis Vaccine 47 Omacor ® 47 NDA Submission 47 FDA Orphan Drug 47 CIP TRAMADOL ER 47 Vectibix panitumumab 47 Teplizumab 47 diarrhea predominant irritable 47 molecular imaging radiopharmaceutical 47 selective immunoproteasome inhibitor 47 Homspera TM 47 Vaccinogen 47 Somatuline R Depot 47 LEVADEX ™ 47 Prodarsan 47 HepeX B 47 Protein Biomarker 47 Nanoemulsion 47 Evoltra 47 Preotact R 47 Ampligen R 47 Vascular Wrap TM 47 Demonstrates Significant 47 adalimumab Humira 47 #D#C# 47 Levocetirizine 47 Centralized Procedure 47 Achieves Primary Endpoint 47 Efficacy Trial 47 Velac 47 BioDelivery Sciences Announces 47 ThermoDox R 47 II Clinical Trial 47 SinuNase TM 47 LUMINATE 47 Ovarian Cancer Treatment 47 Therapeutic Efficacy 47 Phase IIa clinical trials 47 Zenpep 47 Sular formulation 47 Glaucoma Treatment 47 Aegerion 47 Immunomedics Announces 47 Oligonucleotides 47 Sanvar R 47 Fidaxomicin 47 PNP inhibitor 47 vapreotide acetate 47 Uplyso 47 Presents Preclinical Data 47 Fosphenytoin 47 Nimotuzumab 47 Cancer Therapies 47 Milestone Payment 47 faropenem medoxomil 47 PEG SN# 47 ImmunoCellular Therapeutics 47 CytoFabTM 47 ALN TTR 47 Pfizer maraviroc 47 Orathecin 47 Cefazolin 47 preclinical efficacy 47 JAK2 inhibitor 47 Azilect ® 47 Orphan designation 47 investigational protease inhibitor 47 Certican 47 IND Investigational New 47 OHR/AVR# 47 injectable antibiotic 47 Treatment Approaches 47 HCV polymerase inhibitor 47 Benazepril 47 JAK2 Inhibitor 47 RNA Therapeutics 47 Aurograb 47 HoFH 47 SARMs 47 adrenergic regulation 47 Neurodex 47 HepaGam B 47 BEMA Granisetron 47 Accelerated Approval 47 selective androgen receptor modulator 47 Release Capsules 47 Systemic Sclerosis 47 Posaconazole 47 Generic Versions 47 Polymer Microspheres 47 Cloretazine ® 47 histone deacetylase HDAC inhibitor 47 Novel Approaches 47 Synerx Pharma 47 Interferon beta 1a 47 Alferon N Injection 47 M Enoxaparin 47 Elagolix 47 dasatinib Sprycel ® 47 First Patient Dosed 47 defensin mimetic antibiotic 47 Aryplase 47 MOVIPREP R 47 PREOS 47 Telatinib 47 personalized immunotherapy 47 ORENCIA R 47 ASONEP 47 carbapenem 47 MyVax 47 Fresenius Biotech 47 Rotarix ® 47 Metformin GR 47 FOR FURTHER INFORMATION ABOUT 47 TRX1 47 investigational compound 47 LHRH antagonist 47 Chemokine 47 Sym# 47 Soliris eculizumab 47 Ocrelizumab 47 Diamyd Medical Diamyd 47 Diamyd ® 47 HEPLISAV TM 47 Milestone Payments 47 Valganciclovir 47 MK #B 47 Arixtra 47 VIVITROL ® 47 Rebif ® 47 Bupropion HCl ER 47 Awarded Qualifying Therapeutic 47 novel synthetic peptide 46 Golimumab 46 Rapaflo 46 RECOTHROM R 46 Anti Infectives 46 Allovectin 7 R 46 FlutiformTM 46 Betaseron ® 46 VitiGam 46 MIS# 46 Lupin Pharmaceuticals 46 Patient Enrollment 46 Microplasmin 46 Linjeta TM 46 Rescula 46 CytoFab 46 Telaprevir 46 Clindamycin 46 PLAVIX ® 46 lurasidone 46 Archemix Corp. 46 Evamist TM 46 Targeted Therapies 46 ALN PCS 46 Preclinical studies suggest 46 Toxicological Sciences 46 trastuzumab DM1 T DM1 46 Gendux 46 tolevamer 46 PHASE III 46 PROTONIX 46 Clinical Trial Evaluating 46 Premarket Approval Application 46 AAG geldanamycin analog 46 Ferumoxytol 46 Antisense Drug 46 Phase 2b Clinical Trial 46 selective androgen receptor modulators 46 BLA filing 46 New Chemical Entities 46 Fast Track Designation 46 ALGRX 46 ULTRASE 46 Shigamabs ® 46 Gleevec imatinib mesylate 46 Valacyclovir 46 alvimopan Investigational 46 Prednisporin TM 46 drug GAP #B# 46 Elan NanoCrystal 46 Addrenex 46 Ofloxacin 46 SNT MC# 46 Announces Tentative Approval 46 Onalta ™ 46 Dosage Strengths 46 Alfacell proprietary ribonuclease 46 Reclast Aclasta 46 PDL# 46 Aegis Therapeutics 46 Gynazole 1 46 SBIR Grant 46 DOS# 46 Expanded Indication 46 Brain Plasticity 46 Orphan Drug designations 46 InvaGen 46 IMA# 46 SEBIVO 46 ezogabine 46 Ruconest 46 MBP# [001] 46 Calcium Acetate 46 NICOSAN TM 46 Circ Pharma 46 Therapeutic Vaccines 46 LEVADEX TM 46 Sumatriptan Succinate 46 THALOMID 46 Onalta 46 Evista raloxifene 46 Neurotoxicity 46 peginesatide 46 apaziquone 46 Marketing Authorization Applications 46 Virulizin 46 IV Busulfex 46 Motility 46 Fludase 46 candidate deforolimus 46 NexACT ® 46 Zingo TM 46 clinical trials 46 Innate Immunity 46 ARRY # 46 Emezine 46 Taro Receives 46 RTP #i 46 Genes Identified 46 AQ4N 46 Breast Cancer Metastasis 46 Soriatane 46 Flutiform ™ 46 TransVax tm 46 Ketorolac 46 Oral Solution 46 TRANSDUR Bupivacaine 46 Zybrestat 46 Sublinox 46 Syntonix 46 Piperacillin 46 Monoclonal antibody 46 Oxaliplatin Injection 46 Commence Phase 46 TMC# [002] 46 Marketing Authorization 46 MAA submission 46 Aphthasol R 46 Delhi Jan.# ANI 46 voclosporin 46 liver resection surgeries 46 incyclinide 46 Aloxi ® 46 EGRIFTA TM 46 Personalized Immunotherapy 46 PLK1 SNALP 46 Ixempra 46 novel histone deacetylase 46 Xcytrin R 46 BEMA TM Fentanyl 46 Satraplatin 46 Didanosine 46 BRIM2 46 Phase IIb trials 46 Kissei Pharmaceutical 46 EndoTAG TM 46 Ecallantide 46 Cimzia TM